146 related articles for article (PubMed ID: 28358810)
1. Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers.
Ryuge S; Sato Y; Nagashio R; Hiyoshi Y; Katono K; Igawa S; Nakashima H; Shiomi K; Ichinoe M; Murakumo Y; Saegusa M; Satoh Y; Masuda N
PLoS One; 2017; 12(3):e0173886. PubMed ID: 28358810
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung.
Ryuge S; Sato Y; Jiang SX; Wang G; Matsumoto T; Katono K; Inoue H; Iyoda A; Satoh Y; Yoshimura H; Masuda N
Lung Cancer; 2012 Aug; 77(2):415-20. PubMed ID: 22572237
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of nestin expression in resected non-small cell lung cancer.
Ryuge S; Sato Y; Wang GQ; Matsumoto T; Jiang SX; Katono K; Inoue H; Satoh Y; Masuda N
Chest; 2011 Apr; 139(4):862-869. PubMed ID: 20829334
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression.
Jiang W; Fan H; Qian C; Ding J; Wang Q; Pang X
BMC Cancer; 2016 Jan; 16():16. PubMed ID: 26758745
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
[TBL] [Abstract][Full Text] [Related]
7. Positive expression of pro-opiomelanocortin (POMC) is a novel independent poor prognostic marker in surgically resected non-small cell lung cancer.
Hao L; Zhao X; Zhang B; Li C; Wang C
Tumour Biol; 2015 Mar; 36(3):1811-7. PubMed ID: 25377161
[TBL] [Abstract][Full Text] [Related]
8. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
9. Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer.
Williams CD; Gajra A; Ganti AK; Kelley MJ
Cancer; 2014 Jul; 120(13):1939-47. PubMed ID: 24668613
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients.
Song YJ; Wang LX; Hong YQ; Lu ZH; Tong Q; Fang XZ; Tan J
Tumour Biol; 2016 Apr; 37(4):5285-93. PubMed ID: 26561466
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.
Hald SM; Kiselev Y; Al-Saad S; Richardsen E; Johannessen C; Eilertsen M; Kilvaer TK; Al-Shibli K; Andersen S; Busund LT; Bremnes RM; Donnem T
BMC Cancer; 2015 May; 15():441. PubMed ID: 26021984
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy.
Kusuhara S; Igawa S; Ichinoe M; Nagashio R; Kuchitsu Y; Hiyoshi Y; Shiomi K; Murakumo Y; Saegusa M; Satoh Y; Sato Y; Naoki K
Thorac Cancer; 2021 May; 12(10):1570-1578. PubMed ID: 33793071
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
14. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of filamin-A protein is associated with aggressive phenotype and poor survival outcomes in NSCLC patients treated with platinum-based combination chemotherapy.
Gachechiladze M; Skarda J; Janikova M; Mgebrishvili G; Kharaishvili G; Kolek V; Grygarkova I; Klein J; Poprachova A; Arabuli M; Kolar Z
Neoplasma; 2016; 63(2):274-81. PubMed ID: 26774150
[TBL] [Abstract][Full Text] [Related]
16. TAZ is an independent prognostic factor in non-small cell lung carcinoma: Elucidation at protein level.
Malik SA; Khan MS; Dar M; Hussain MU; Mudassar S
Cancer Biomark; 2017; 18(4):389-395. PubMed ID: 28128737
[TBL] [Abstract][Full Text] [Related]
17. KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer.
Liu YZ; Yang H; Cao J; Jiang YY; Hao JJ; Xu X; Cai Y; Wang MR
Sci Rep; 2016 Apr; 6():24786. PubMed ID: 27098511
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of claudin-3 is associated with a poor prognosis and EMT in completely resected squamous cell lung carcinoma.
Che J; Yang Y; Xiao J; Zhao P; Yan B; Dong S; Cao B
Tumour Biol; 2015 Aug; 36(8):6559-68. PubMed ID: 25820701
[TBL] [Abstract][Full Text] [Related]
19. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer.
Guo NL; Dowlati A; Raese RA; Dong C; Chen G; Beer DG; Shaffer J; Singh S; Bokhary U; Liu L; Howington J; Hensing T; Qian Y
EBioMedicine; 2018 Jun; 32():102-110. PubMed ID: 29861409
[TBL] [Abstract][Full Text] [Related]
20. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study.
Lin ZZ; Shau WY; Shao YY; Yang YY; Kuo RN; Yang JC; Lai MS
Oncologist; 2012; 17(10):1294-302. PubMed ID: 22826374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
